Table 1 Patient and disease characteristics
Patient characteristics | No-ATG | ATG | p value |
|---|---|---|---|
Number of patients | 421 | 145 | |
Recipient age at SCT (years, range) | 43.7 (18–68) | 48.8 (20–69) | 0.002 |
Recipient gender, n (%) | 0.24 | ||
Male | 215 (51.3%) | 82 (56.9%) | |
Female | 204 (48.7%) | 62 (43.1%) | |
Year of SCT (median), year (%) | 2011 (2006–2013) | 2012 (2006–2013) | <10−5 |
Interval from diagnosis to SCT (median days) | 156 | 156 | 0.79 |
Median follow-up a (months, range) | 16 (1.5–93) | 21 (1–106) | 0.81 |
Donor age (years, range) | 41 (8–70) | 47 (10–65) | 0.003 |
Donor gender, n (%) | |||
Male | 236 (56.3%) | 70 (48.6%) | 0.11 |
Female | 183 (43.7%) | 74 (51.4%) | |
Female donor to male recipient, n (%) | 96 (23%) | 44 (30.8%) | 0.06 |
Diagnosis, n (%) | 0.05 | ||
De novo AML | 391 (92.9%) | 127 (87.6%) | |
Secondary AML | 30 (7.1%) | 18 (12.4%) | |
Cytogenetics in de novo AML, n (% of available data) | 0.60 | ||
Good | 18 (16.2%) | 6 (9%) | |
Intermediate | 76 (68.5%) | 50 (74.6%) | |
Poor | 17 (15.3%) | 11 (16.4%) | |
Not available/failed | 280 | 60 | |
Source of SC, n (%) | <10−4 | ||
BM | 84 (20%) | 10 (6.9%) | |
PB | 337 (80%) | 135 (93.1%) | |
In vivo T cell depletion, n (%) | |||
Thymoglobuline | 0 | 138 (95.2%) | |
ATG Fresenius | 4 (2.8%) | ||
Missing brand of ATG | 3 (2%) | ||
Mean dose of thymoglobuline (mg/kg) (range) | 5 (2.5–15.8) | ||
Thymo ≤ 6 mg/kg | 98 (73.7%) | ||
Thymo > 6 mg/kg | 35 (26.3%) | ||
Unknown dose of thymoglobuline | 12 | ||
Post-transplant GVHD prophylaxis | <10−4 | ||
CsA | 4 (1%) | 42 (29%) | |
CsA + MTX | 372 (88.4%) | 57 (39.3%) | |
CsA/FK 506 + MMF | 35 (8.3%) | 17 (11.7%) | |
Other | 10 (2.4%) | 29 (20%) | |
Patient positive CMV serology, n (%) | 362 (87%) | 107 (74.3%) | <10−4 |
Donor positive CMV serology, n (%) | 330 (80.1%) | 104 (72.7%) | 0.07 |
CMV risk, n (%) | 0.008 | ||
Low | 33 (8%) | 22 (15.5%) | |
Intermediate | 328 (77.9%) | 103 (71%) | |
High | 49 (12%) | 17 (12%) | |